Terumo Set To Build On Long-Term VAD Investments With Upcoming Trials

Terumo Corporation's long journey toward comercialization of the DuraHeart ventricular assist device is about to take a major step forward with the start of a U.S. "bridge-to-transplant" trial and the upcoming launch of a "destination therapy" trial

More from Archive

More from Medtech Insight